Numerous studies have documented that melatonin exhibits antiangiogenic actions, in part, by downregulating VEGF and HIF-1α in several cancers via different mechanisms; the cancer types included breast [16, 149], prostate [150–152], colon [153, 154], liver [155], and pancreatic cancer [156, 157]. The gene discussed is HIF1A; the disease is cancer.